Experimental drug daraxonrasib doubles survival in advanced pancreatic cancer trial
Published 1 d ago1 sourceEvidence: Reported
Phase trial data for daily oral daraxonrasib shows tumour shrinkage and possible elimination in some pancreatic cancer patients, a disease with historically poor outcomes. Results are early-stage and not yet peer-reviewed or FDA-approved; durability and survival benefit remain unproven. If confirmed, this would mark a major therapeutic advance in one of the deadliest cancers.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Published 1 d ago1 sourceEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 15 h ago2 sourcesEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 4 h ago1 sourceEvidence: Reported
Published 17 h ago1 sourceEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported